WO2012104025A2 - Préparations probiotiques balnéologiques contenant des lipides et leurs utilisations - Google Patents

Préparations probiotiques balnéologiques contenant des lipides et leurs utilisations Download PDF

Info

Publication number
WO2012104025A2
WO2012104025A2 PCT/EP2012/000250 EP2012000250W WO2012104025A2 WO 2012104025 A2 WO2012104025 A2 WO 2012104025A2 EP 2012000250 W EP2012000250 W EP 2012000250W WO 2012104025 A2 WO2012104025 A2 WO 2012104025A2
Authority
WO
WIPO (PCT)
Prior art keywords
oil
bath
weight
preparation
mixtures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2012/000250
Other languages
German (de)
English (en)
Other versions
WO2012104025A3 (fr
Inventor
Jürgen Ebinger
Martina Holzem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merz Pharma GmbH and Co KGaA
Original Assignee
Merz Pharma GmbH and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma GmbH and Co KGaA filed Critical Merz Pharma GmbH and Co KGaA
Priority to EP12702178.0A priority Critical patent/EP2670385A2/fr
Publication of WO2012104025A2 publication Critical patent/WO2012104025A2/fr
Publication of WO2012104025A3 publication Critical patent/WO2012104025A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20—Halogens; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30—Characterized by the absence of a particular group of ingredients
    • A61K2800/31—Anhydrous

Definitions

  • the present invention relates to solid or liquid, in particular cosmetic, dermatological or medicinal balneological preparations for bathing or showering, which are essentially free of water (with a low water content of less than 1% by weight), and a lipid content with preferably at least one liquid lipid , further dispersants, and a content of probiotic agents selected mainly from bacteria of the genus Lactobacillus and Bifidobacteria exhibit.
  • the skin can be supplied with the probiotic active ingredients in a holistic manner over the entire surface, including the mucous membranes, in the sense of a nourishing effect by maintaining and possibly rebuilding their healthy microbial status, while at the same time being purified and with lipids is supplied.
  • the preparations have a required for the effect described effect stability of the microorganisms without further special measures for this purpose.
  • Balneological additives for use in the tub or shower have long been known.
  • water-free, in particular oil-containing products are distinguished from water-containing products, which depending on the additives may have different consistencies from liquid to gelatinous.
  • They mainly contain surfactants for cleansing the skin, and preferably lipidic substances, in order to rebuild the lipid film removed by the use of water and surfactants.
  • Preference is given to using essential oils / extracts depending on the intended effect.
  • Non-aqueous formulations containing liposome-forming substances are also particularly suitable. As a result, an improved drug delivery and thus a higher efficacy in the application should be made.
  • Probiotics are preparations containing viable microorganisms, which in particular can be used orally and thereby exert a health-promoting influence by improving the internal microbial status. More recently, products containing microorganisms have also been described which can be applied topically for the treatment of a bacterial or fungal infection or for the disinfection of surfaces.
  • EP 1629846 A2 describes a composition for topical therapeutic skin / mucous membrane application z. In the form of an oil or a powder containing a Bacillus strain. From the parallel DE 69832267 T4 an antimicrobial composition with a Bacillus species (B. coagulans) z. B. with oil or powder as a carrier, which are used in particular together with growth-promoting fructo-oligosaccharides, used for the treatment of a bacterial infection or skin diseases such as acne.
  • Bacillus species B. coagulans
  • Bacillus species are known to be spore-forming, mobile and thus relatively stable microorganisms, while z.
  • B. Lactobacilli are immobile and not spore-forming.
  • the problem with the use of probiotic organisms is that on the one hand in the basis of a sufficient number of viable germs should be present and on the other hand must be storable.
  • coatings or microencapsulation are therefore proposed, see DE 69634171 T4.
  • EP 0131114 B1 describes a special drying method for preserving a particular Lactobacillus species for their use in food production.
  • a suitable base is chosen such as an oil in water - lotion or a spray with liposomally packed germs or a surfactant-free oil (olive oil, almond oil, grapeseed oil), in particular synthetically processed sesame oil.
  • the germs especially acid-stable lactobacilli bacteria
  • surfactant dispersants are not used here in anhydrous bases.
  • water- containing products are preferably added Fructo-Oligosacchride (see paragraphs 0038, 0039).
  • an anhydrous base with surfactants is to be used, the base is first prepared separately, for. B. bath oil from mineral oil and laureth 4 described ben as in the above-mentioned DE 69832267 T2. This base is added to the bathing liquor and then added for the disinfection application, the separately present dry bacillus coagulum spores, so that thereof about 5x10 9 are present, see paragraphs 0068 and 0101, DE 69832267 T2.
  • the separate administration enables a certain stability of the microorganisms, which is essential in particular for therapeutic antimicrobial treatment and disinfection.
  • US 2009/0232785 A1 discloses solutions, such as aqueous or aqueous-alcoholic products for the treatment of sensitive or dry skin, which have a combination of microorganisms and an unsaturated fatty acid.
  • WO 2010/103374 suspensions for pediatric use which have up to 30% of microorganisms which are coated (encapsulated) with at least one plant lipid.
  • JP 03041019 A describes bath solutions containing 30-60% of a specially fermented microorganism mixture of lactobacillus and / or lactic acid bacteria.
  • JP 63179829 A antibacterial preparations are described which bacterial strains selected from Streptococcus, Lactobacillus, or Bifidus or aqueous extracts thereof.
  • JP 62175419 A relates to a combination of dried plants, perfume substances and magnetite salts as a bath additive for the release of selenium, germanium, platinum, gold, etc., which also have Bifdus bacteria and a protease. When used in the bath, this preparation is intended to warm the body through the combined effect of perfume, enzymes, bacteria and minerals.
  • a preparation could be provided especially for cleaning and care, in which the desired probiotic active ingredient, regardless of a specific type, already contained in a suitable, especially with respect to the microbial skin status' conservative amount and thus in the application especially in the bath despite the presence of surfactant-acting dispersant uniform distribution would be possible.
  • a ready-to-use preparation should also have sufficient stability to ensure an equally sufficient amount of viable microorganism.
  • the present invention has for its object to provide a simply hand zuschide preparation for balneological applications with cleaning effect in a simple way, with which the microbial status of the skin despite the cleaning process during bathing received, if necessary, can also be improved, while a Greasing takes place, resulting in a total nourishing effect.
  • a flowable, above all liquid or solid balneological preparation with a free-flowing, especially liquid, substantially anhydrous lipid base or with a substantially anhydrous solid lipid-containing base based on a carrier selected from mineral salt, Effervescent salt, urea, provides.
  • a content of probiotic microorganisms in an amount of from 10 2 to 10 9 germs / g (weight) of the preparation together with one or more surface active dispersants selected from nonionic surfactants, anionic surfactants or mixtures thereof.
  • the probiotics selected from bacteria of the genera Lactobacillus, Bifidus, or mixtures thereof.
  • the base may comprise active ingredients such as essential oils, vitamins, as well as conventional galenic additives in an amount of 0, preferably 0.1 to 30 wt.%, Based on the total weight of the mixture.
  • Substantially anhydrous in the present application means a water content which is possible from the raw materials used and which in total should not exceed 1% by weight and preferably less than 0.5% by weight, based on the total weight of the preparation.
  • the balneological preparations according to the invention do not comprise any fructo-oligosaccharides, nor do the micro-organisms used have to be encapsulated or provided with certain coatings to increase the stability.
  • non-spore-forming microorganisms are used, they remain sufficiently stable, in particular if the said lipids are selected for this purpose.
  • These include, in particular, natural liquid oils containing at least 50% of oleic and linoleic acids, hydrogenated derivatives thereof and mixtures of these lipid components.
  • vesicle formers such as lecithins may also be present.
  • the liquid preparation (with essentially anhydrous liquid lipid-containing base) preferably comprises 40 to 90, especially 50 to 90% by weight of liquid lipids (in particular natural oils having an oil and linoleic acid content ( ⁇ ) of at least 50% by weight). or mixtures thereof), 1 to 30, especially 1 to 20, in particular 1 to 15 wt.% Dispersing agent, 10 2 to 10 9 / g preparation probiotic germs, 0 to 20, especially 0.1 to 20 or 0.1 up to 15% by weight of additives and optionally (0 to 15, especially 0.5 to 15% by weight) of additional active ingredients and less than 1% by weight of water.
  • liquid lipids in particular natural oils having an oil and linoleic acid content ( ⁇ ) of at least 50% by weight). or mixtures thereof
  • 1 to 30, especially 1 to 20, in particular 1 to 15 wt.% Dispersing agent 10 2 to 10 9 / g preparation probiotic germs, 0 to 20, especially 0.1 to 20 or 0.1 up to 15% by weight of additives and optionally (0 to 15, especially
  • mineral salts such as chlorides, sulfates of alkali and alkaline earth metals (NaCI, CaSO 4 , MgSO.); KBr
  • lipids 1 to 30, especially 1, 5 to 20, especially 2 to 15 wt
  • a part or the total amount of mineral salts may be replaced by a suitable effervescent composition and the preparation may also be tabletted.
  • a suitable effervescent composition may in this respect 20- 85%, in particular 60-80%, a carbonate / bicarbonate-acid mixture, 0 to 20 wt.
  • Mineral salts as described above; 1-25% by weight, especially 1 to 15% by weight, in particular 1.5 to 8% by weight, of one or more lipids as mentioned; 0.1-20%, especially 0.1-5%, of one or more dispersants; 10 2 to 10 9 probiotic germs / g of preparation and 0-20%, preferably 0.1 to 20% by weight of additives and / or additional active ingredients (eg 0.5 to 15, especially up to 10% by weight) ,
  • solid preparations with lipid-containing substantially anhydrous (solid) base may also be urea, z. B. 80 to 95 wt.%, Are used.
  • Solid preparation forms are colloids such as dextrins, plant colloids or higher molecular weight cellulose derivatives preferred additives.
  • the dispersants are selected from nonionic, in particular polyoxy-preferably polyethoxylated, or anionic surface-active substances, in particular from one or more of each of these two groups.
  • the present invention relates to balneological preparations especially for cosmetic, and also for dermatological applications or possibly also for medical applications, depending on additional active components and combinations. They therefore comprise, in addition to the content of 10 2 to 10 9 , preferably 10 3 to 10 9 , in particular 10 5 to 10 9 germs / g Preparation of probiotic microorganisms suitable application-related or product-related additives and optionally additional active ingredients as described below.
  • the application is carried out by pouring the liquid or sprinkling of the solid preparation in the bathing liquor or directly, z. B. in the shower.
  • Lipids The preparations of the present invention initially comprise one or more lipids in an amount adapted to the particular product and form the liquid base in the case of liquid products.
  • lipid component is meant only the amount of lipids as described in this category.
  • Other lipid-like or lipid-soluble substances which are or may be present in preparations according to the invention (such as additives, additional active ingredients) are not included in the lipid component designated according to the application and, if present, are present separately.
  • the lipids may be selected from the group comprising natural lipids, especially natural liquid oils and hydrogenated derivatives thereof, or mixtures thereof.
  • the lipids according to the invention include above all liquid lipids, in particular oils, selected especially from natural oils with a high content of oleic acid and (+) linoleic acid.
  • Particularly preferred lipids include, in particular, liquid oils whose total proportion ( ⁇ ) of oleic acid + linoleic acid is at least 50%, in particular more than 60% and very particularly preferably at least 75%. (Information on the oleic acid-linoleic acid content of the above-described oils can be found, for example, in the DAZ, Volume 150, Volume 02.09.2010, No. 35, pages 3925-3934).
  • lipid mixture at least one substance with a total proportion (l) of oleic acid + linoleic acid of at least 75% by weight, preferably at least 80% by weight, is present.
  • Lipids suitable for preparations according to the invention are apricot kernel oil, avocado oil, borage seed oil, thistle oil, peanut oil, hazelnut oil, pumpkin seed oil, corn oil, almond oil, marula oil, macademia nut oil, poppy seed oil, evening primrose oil, olive oil, palm oil, pine nut oil, rice germ oil, sea buckthorn oil, sesame oil, soybean oil, Sunflower oil, grape seed oil, walnut oil, wheat germ oil and the hydrogenated derivatives thereof, such as hydrogenated sunflower oil, hydrogenated palm oil, hydrogenated soybean oil, hydrogenated tartar oil, hydrogenated olive oil or mixtures thereof.
  • suitable oils of the type described above are mainly selected from olive oil, sunflower, soybean oil, apricot kernels, Grapeseed oil, hazelnut oil, poppy seed, peanut, almond, wheat germ, sesame safflower oil, avocado oil, borage seed oil, sea buckthorn oil, corn oil, walnut oil, nightcap oil, palm oil, pine nut oil, rice germ oil, pumpkin seed oil, marula oil, or mixtures of these oils or mixtures with the hydrogenated (rather semisolid) derivatives thereof, in particular palm oil, sunflower oil and soybean oil (in each case hydrogenated).
  • Very particularly preferred liquid lipids are vegetable oils selected from almond oil, avocado oil, marula oil, apricot kernel oil, hazelnut oil, sea buckthorn oil, soybean oil or mixtures thereof.
  • hydrogenated lipid derivatives (waxy semi-solid or solid) or solid to waxy lipids are hydrogenated soybean oil, hydrogenated palm oil, hydrogenated sunflower oil or mixtures thereof.
  • the lipids are in preparations according to the invention preferably in a total amount of 25, especially 50 to 90 wt.%, Especially 60 to 85% by weight (flowable, liquid anhydrous preparations), or 1 to 30 wt.%, In particular 1 to 15, especially 1 to 8, especially 1, 3 to 6 wt.% (Solid preparations) contain as described above.
  • preparations according to the application comprise at least one liquid lipid, preferably selected from sunflower, soybean, olive oil, peach kernel, apricot kernel, grape seed, peanut, almond, mink, wheat germ, sesame, thistle almond , avocado oil, palm oil, pine nut oil, rice germ oil, macadamia nut oil, palm kernel oil, papaya oil, sea buckthorn oil (each having a oleic acid-total oleic acid content (£) of at least 50% by weight), together with one or more vesicle-forming agents, preferably selected from lecithins, phospholipids, sphingosines, cerebrosides , Ceramides or Gemi- see thereof as described below.
  • vesicle-forming agents preferably selected from lecithins, phospholipids, sphingosines, cerebrosides , Ceramides or Gemi- see thereof as described below.
  • inventive, especially solid preparations comprise one or more liquid oils as described above together with one or more hydrogenated derivatives thereof as described, especially selected from sunflower oil, soybean oil and palm oil (each hydrogenated), or mixtures thereof with the above-mentioned liquid oils.
  • one or more vesicle formers, z. B. selected from lecithins, phospholipids, sphingosines, cerebrosides, ceramides or mixtures thereof as described in more detail below.
  • the preparations further comprise one or more (surface-active) dispersants (surfactants).
  • surfactants Suitable for this purpose are dispersants having an HLB value of between 7 and 11 (such as W / O dispersant) and dispersants having an HLB value of from 13 (such as O / W dispersant).
  • dispersants having an HLB value of between 7 and 11 such as W / O dispersant
  • dispersants having an HLB value of from 13 such as O / W dispersant
  • specific oil-soluble, water-dispersible compositions having an HLB value between 7.5 and 12.5, as described below.
  • the dispersant or dispersants are selected from:
  • nonionic dispersants of the group comprising:
  • (W / O) - agent having an HLB value of 7-11 selected from cetearyl alcohol, glycerol stearate; low-polyethoxylated or -propoxylated or else mixed low-polyoxylated Ce-22 fatty alcohols having a degree of ethoxylation and / or degree of propoxylation (EO / PO degree) of 1-7 EO;
  • aiii) (O / W) agent having an HLB of 13-25 selected from higher polyoxyethylated / and / or propoxylated Ce-22 fatty alcohols; ethoxylated and / or propoxylated C 12-22 fatty acids having ethoxylation or propoxylation degrees of 8-25;
  • sugar esters or sugar ethers of C 12-22 fatty acids or Ce-22 fatty alcohols polyoxyethylated and / or polyoxypropylated sugar esters of C12-C18 fatty acids, wherein the EO or PO degree is 8-25; or mixtures thereof;
  • anionic compounds of the group comprising:
  • Sodium salts such as sodium lauryl sulfate, sodium lauryl ether sulfate or their ethoxylated / and / or propoxylated derivatives having 1 to 6 EO; bii) (alkyl) -Ci 2 -C 22 fatty alcohol amino acid ester compounds, in particular alkali salts thereof, wherein the amino acids are selected from glycine, taurine, or mixtures thereof;
  • As (W / O) dispersing components it is preferable to select those having an HLB of 7-1 1, preferably 7.5 to 10.
  • nonionic substances ai) such as fatty alcohols, such as cetearyl alcohol, or monoglycerides, such as glycerol stearate; furthermore low-polyethoxylated or -pro-polyoxylated or else mixed low-polyoxylated Ce-22-fatty alcohols having a degree of ethoxylation and / or degree of propoxylation (EO / PO degree) of 1-5 EO.
  • EO / PO degree degree of propoxylation
  • low polyoxylated Ce-22 fatty alcohols having an EO degree of 1-5 include, in particular, macrogol (polyethylene glycol) lauryl ethers having 1 to 4 EO units such as laureth 2, laureth-3, laureth-4 or mixtures thereof.
  • O / W dispersing components those having an HLB value of 13-40, especially 13-25, especially 13.5 to 20, especially 13.5-17, are preferably selected.
  • These include in particular higher polyoxyethylated / and / or -propoxylated Ce-22 fatty alcohols (especially alkyl-Cio-Cie fatty alcohol alkoxylates) or such ethoxylated and / or propoxylated C 12-22 fatty acids having degrees of ethoxylation or propoxylation of 8-25 or mixtures thereof such as (HLB values in parentheses): polyoxypropylene (15) stearyl ether or, polyoxyethylene sorbitan monooleate (15.0), polyoxyethylene sorbitan monostearate or palmitate 15.0), polyoxyethylene stearyl ether (15.3), polyoxyethylene oleyl ethers (15.3), polyoxyethylene oxypropylene monostearate (15.7), polyoxyethylene fatty alcohol ether (16.0), polyoxyethylene monostea
  • sugar esters or sugar ethers of C 12-22 fatty acids or Ce-22 fatty alcohols include in particular sugar esters of C 12 -C 18 saturated, unsaturated, partially saturated fatty acids; Polyoxyethylated and / or polyoxypropylated sugar esters of Ci2-Ci 8 fatty acids, wherein the EO or PO degree is 8-25.
  • the sugar ethers include those of C8-C20 saturated, unsaturated, partially saturated fatty alcohols; or of polyoxyethylated and / or polyoxypropylated sugar ethers of these C8-C20 fatty alcohols.
  • the EO or PO degree is between 8 and 25.
  • sugars are glucose, methyl glucose, sucrose and, as acids or alcohols, the C16-C18 fatty acids / alcohols. Preference is given to ethoxylated products.
  • the acid or alcohol components are derived primarily from aliphatic carboxylic acids / alcohols. These include in particular caprylic acid, capric acid, lauric acid, yristinic acid, palmitic acid, stearic acid, oleic acid and also mixtures thereof or fatty alcohols (oleyl alcohol, lauryl alcohol, stearyl alcohol etc.).
  • the dispersing components are selected from (bi) anionic compounds, such as e.g. As Ce-22-alkyl sulfates or Ce-22 alkyl ether sulfates or their alkali metal, in particular sodium salts such as sodium lauryl sulfate, sodium lauryl ether.
  • anionic compounds such as e.g. As Ce-22-alkyl sulfates or Ce-22 alkyl ether sulfates or their alkali metal, in particular sodium salts such as sodium lauryl sulfate, sodium lauryl ether.
  • the dispersing components can also be selected from (alkyl) -C 12 -C 22 fatty alcohol amino acid ester compounds (bi), in particular an alkali metal salt thereof, wherein the amino acids are selected from glycine, taurine, such as oleyl, lauryl taurate, Natriummethyloleyltaurat u .ä .. These can be used as salts such.
  • these can be used as salts such.
  • Alkali alkaline earth salts Na / K-Ca-, Mg-chlorode, sulfates, - phosphates.
  • Amino acid ester compounds (bii) as described above are particularly suitable for solid preparations, and especially in combination with nonionic dispersants ago all lower or higher oxylated alkyl esters / ethers.
  • Suitable dispersants (aii) are, as mentioned, oil-soluble, water-dispersible polyoxyethylated fatty alcohols / fatty acids (alkyl chain length as described) with an HLB value of 7.5 to 12, preferably 7.5 to 10 and an EO degree of 1 Above all (EO grade in parentheses): polyoxyethylene lauryl ether having 1 to 15 EO units, medium chain length such as polyoxyethylene (5) oleyl ether, polyoxyethylene (7) glyceryl cocoate, coconut fatty acid diethanolamide, mono / di / tri / ( alkyl tetraglycol ether), lol phosphonic acid ester, polyoxyethylene glycerol trioleate, polyoxyethylene sorbitan tristearate, polyoxypropylene (15) stearyl ether.
  • polyoxyethylene lauryl ether having 1 to 15 EO units, medium chain length such as polyoxyethylene (5) oleyl ether, polyoxyethylene (7) glyceryl cocoate, coconut
  • polyoxyethylene lauryl ethers having 1 to 4 EO units, polyoxyethylene (7) glycerol cocoate, coconut fatty acid diethanolamide or their Mixtures, in particular also in combination with one or more of the above-mentioned anionic dispersants.
  • Isethionates are preferably not used.
  • nonionic (eg. W / O) dispersant with anionic (eg 0 / W) dispersants in particular nonionic (eg. W / O) dispersant with anionic (eg 0 / W) dispersants.
  • non-ionic dispersants especially oxylated, especially ethoxylated alkyl esters or preferably ethoxylated alkyl ethers ai), aii) as described above, are used.
  • Particularly preferred dispersing components are selected from polyethoxylated or low-bepolypropoxyl striv or also mixed oxyl believing C12- 18 fatty alcohols with a degree of ethoxylation / propoxylation (EO / PO degrees) 1-5, in particular with an EO degree of 2-4 especially such lauryl ether components, in particular in combination with anionic agents such as Ce-22 alkyl sulfates, Ce-22 - alkyl ether sulfates and C12-Cie fatty alcohol taurates, in particular sodium methyl oleyl taurate.
  • the dispersing components are present in a (total) amount adapted to the respective dosage form.
  • the total amount of dispersants may be in solid products z. B. 1 to 12 wt.%, Preferably 1 to 10 wt.%, Especially 2 to 7 wt.%, In flowable (liquid) products 4 to 30 wt.%, Especially 4 to 25 wt%.
  • Probiotic bacteria which can be used in the present invention include in particular bacteria of the genera Lactobacillus and Bifido such as Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus salivarius, Lactobacillus delbrueckiil, Lactobacillus rhamnosus, Lactobacillus bulgaricus, Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus jensenii; the lactococcus genus including Lactococcus lactis (subsp.
  • Bifidobacterium LA-5 powder ver Bifidobacterium longum, Bifidobacterium infantis, and Bifidobacterium bifidum.
  • the germs are not verkaspselt or are not used liposomal. Particularly suitable are as germs of the genus Lactobacillus acidophilus.
  • acid-tolerant bacteria which can be used according to the invention are Lactobacillus acidophilus La-14; Lactobacillus casei Lc-1 1; Lactobacillus paracasei Lpc-37; Lactobacillus plantarum Lp-115; and Lactobacillus rhamnosus L4-32; (from Danisco, USA, Madison, Wisc).
  • suitable oxygen-tolerant bacteria according to the invention are B. lac- tis Bb12, (available from Chr. Hansen, Denmark) and B. lactis HN019 (DR10) (for example, commercially available from Danisco, USA, Madison, Wisc).
  • Particularly suitable probiotics include, in particular, Lactobacilli, Bifidobacteria.
  • Particularly preferred are the species Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus reuteri, Lactobacillus bifidum, Lactobacillus gasseri, Lactobacillus plantarum, Lactobacillus johnsonii, Lactobacillus rhamnosus, Lactobacillus fermentum, Lactobacillus paracasei, Lactobacillus crispatus, Bifidobacterium longum, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium lactis, Bifidobacterium brevis, Bifidobacterium animalis, Bifidobacterium adolescentis, Bifidobacterium infantis, Lactococcus lactis or else mixtures thereof.
  • microorganisms are commercially available in a suitable form and known as such. They may preferably be used in a dried, non-microencapsulated form, although special coatings are not required.
  • the bacterial species are generally present in pulverized form, revitalizable in an aqueous phase, preferably containing about 30 x 10 9 viable germs per gram of dry matter. They are incorporated in the dosage form according to the invention (balneological preparation) in an amount such that a content of 10 2 to 10 9 , preferably 10 3 to 10 8 , especially 10 3 to 10 6 germs of probiotic or probiotic mixture / g of preparation (accordingly approx. up to 1% by weight). It is further preferable to use the microorganisms and not spores thereof.
  • Compositions according to the invention may also have vesicle formers.
  • sphingolipids e.g., ceramides, cerebrosides, sphingosine, sphingomyelin.
  • ceramides ceramides, cerebrosides, sphingosine, sphingomyelin.
  • the amount of vesicle-forming lipid is 0 to 5 wt.%, Above all, 0.1 to 5 wt.%, Preferably 0.3 to 3 wt.%.
  • vesicle-forming agents are added, an even better balance of the bacterial status and also an improved lipid status of the skin can be achieved.
  • Preferred embodiments of the present invention therefore also comprise one or more liposomal components as described above, in particular phospholipids, lecithins, e.g. B. in an amount of 0.5 to 4 wt.%.
  • additives are selected in amounts between 0 and 20% by weight, in particular 0.5 to 20% by weight, preferably 0.5 and 17% by weight.
  • consistency agents including stabilizers, adsorbents, lubricants, lubricants and disintegrants, especially for solid dosage forms
  • dyes and perfumes include C12-22 fatty acid partial esters of polyhydric C 2 -6 alcohols such as diglycerides e.g. B.
  • Glycerol distearate Polyol C12-22 fatty acid esters such as propylene glycol dicaprylates / dicaprate, or mixtures such as hexyl decanol and hexyldecyl laurate or possibly also waxes such as natural or bleached beeswax (C2C 0-alkyl stearate) or micro wax or hydrocarbon waxes such as mineral wax and Fatty acid amides such as cocoamidobetaines or synthetic waxes such as cetyl palmitate or myristyl myristate, or stearyl stearates.
  • Polyol C12-22 fatty acid esters such as propylene glycol dicaprylates / dicaprate, or mixtures such as hexyl decanol and hexyldecyl laurate or possibly also waxes such as natural or bleached beeswax (C2C 0-alkyl stearate) or micro wax or hydro
  • Stabilizing agents include, for. B. stabilizing antioxidants.
  • protein hydrolysates of vegetable and / or animal origin such as wheat protein hydrolysates and collagen hydrolysates.
  • colloids include polyvinyl pyrrolidone, methyl cellulose and methyl hydroxyethyl cellulose. It is also possible to use adsorbents such as cyclodextrin, dextrin, starch and / or finely divided silica or other silicon dioxide products, lubricants and lubricants and disintegrants such as talc, starch products, cellulose derivatives and carboxymethylated, cross-linked povidone or magnesium stearate, macrogol.
  • adsorbents such as cyclodextrin, dextrin, starch and / or finely divided silica or other silicon dioxide products, lubricants and lubricants and disintegrants such as talc, starch products, cellulose derivatives and carboxymethylated, cross-linked povidone or magnesium stearate, macrogol.
  • Perfumes are z. As the following essential agents (oils, extracts) or synthetic agents, such as. As linalool, geraniol or rose oil. Dyes are, for example, suitable, especially water-soluble, dyes suitable for the purpose mentioned, e.g. Cochenillerot, patent blue and quinoline yellow, u. ⁇ ., Or natural water-soluble dyes such as beetroot extract, or chlorophyll.
  • Preservatives are not required in preparations of the invention and are preferably not used.
  • Acids such as lactic acid, citric acid, tartaric acid, acetic acid, hydrochloric acid, malic acid and the like may optionally be used, as long as the dosage form (eg effervescent salt) requires it.
  • Additional active ingredients which may be present in a total amount of 0.1 to 20, or 0.5 to 20 wt.%, Especially 0.1 or 0.5 to 10 wt.%, Based on the total preparation, are particularly selected from essential oils, plant extracts with the respective effects known to the person skilled in the art, such as stimulating, calming, healing, anticoagulant, refreshing, invigorating and so on
  • Other application-related active substances such as substances that promote circulation, hygienic / dermatological active substances (antifungals, antiseptics), skin-care active substances can also be used here.
  • the essential oils / extracts include for cosmetic / dermatological or possibly medicinal bath additives conventional essential oils / extracts, preferably selected from khaki leaves, mango, figs, lavender oil, cedar wood, lotus flowers, chamomile flowers, ylang ylang, ginkgo, pine needle, cypress, Oranges, rosewood, plum birch leaf extract, aloe vera extract, marigold, hibiscus, burdock root Hamamelis, aquamarine, algae, quince, water lily, cinnamon extract, thyme, mint, lime, orange extracts , Grapefruit, tangerine, juniper, valerian, lemon balm, eucalyptus, thyme, palmarosa, cinnamon, rosemary, rosewood, lemongrass, wild rose, spruce needle, pine needle, ginger, currant, lime blossom, marigold, magnolia, pineapple, guava -, Echinacea, Ivy Leaf Extract Blueberry, Kaki - Melon
  • extracts are prepared in known manner such as. B. produced by steam distillation.
  • essential oils are obtained from the said plants, which are particularly preferred.
  • the extracts can also be obtained with solvent extraction (with alcohols, triglycerides or hydrocarbons, water, mixtures thereof) and then used as such.
  • analogously synthetically produced substances are terpenes and terpenoids, such as camphor, menthol, cineol or mixtures thereof.
  • Suitable care substances are z. Essential unsaturated fatty acids and their esters, e.g. Linoleic or linolenic acid, glyceryl linoleates, glyceryl linolenates.
  • humectants such as glycerol, propylene glycol or polyethylene glycols, polypropylene glycol, butylene glycol, sorbitol or polymers, e.g. Polyquaternium types, collagen or its hydrolysates, amino acids.
  • circulation-promoting substances include (if necessary, in addition to the above-mentioned essential oils / extracts) z.
  • nicotinic acid derivatives such as methyl or tocopheryl nicotinate, alpha- and betahydroxy acids and their derivatives, for.
  • ursolic acid, glycyrrhizinic acid or Glycyrrhetinklare and their derivatives eg.
  • Stearyl glycyrrhetinates potassium glycyrrhinate; Pantothenic acid derivatives, e.g. As D-panthenol, panthenyl triacetate or polyphenols, flavonoids, z.
  • Pantothenic acid derivatives e.g. As D-panthenol, panthenyl triacetate or polyphenols, flavonoids, z.
  • rutin ferulic acid and its esters or isoflavones such as soy isoflavones or coenzyme Q 10.
  • As a hygienic / dermatological-medical agents are, for.
  • dexpanthenol As dexpanthenol, allantoin, bisabolol and minerals and trace elements such as copper, zinc, or their derivatives such as Zincidone ® (zinc PCA-pyrrolidonecarboxylic acid), zinc gluconate or copper gluconate.
  • Zincidone ® Zinc PCA-pyrrolidonecarboxylic acid
  • vitamins or derivatives thereof are vitamins or derivatives thereof.
  • the water-soluble representatives include in particular: vitamin C or suitable derivatives thereof, such as - palmitate, ascorbate calcium / sodium ascorbate, potassium ascorbate, as well as the vitamins of the B group such as B1 (thiamine, eg Thiaminnitrat), B2 (Riboflavin as), B3 (niacin, nicotinic acid and derivatives thereof such as niacinamide), B5 (pantothenic acid) such as calcium pantothenate or provitmain B5; B6 (pyridoxine or pyridoxine hydrochloride or phosphate), B7 (vitamin H, biotin, B9 (folic acid), B12 (cobalamin) or carotenoids such as beta / alpha-carotene, beta-cryptoxanthin, lute
  • B1 thiamine, eg Thiaminnitrat
  • B2 Rosboflavin as
  • B3
  • vitamin C in particular palmitate or Ca ascorbate
  • vitamin E in particular acetate, succinate
  • vitamin B5 in particular acetate, succinate
  • vitamin B7 in particular acetate, succinate
  • Another suitable vitamin combination in probiotic preparations according to the invention comprises vitamin A, in particular the palmitate, vitamin E acetate, beta-carotene, folic acid and / or vitamin B5.
  • vitamin C z.
  • vitamin C palmitate can be combined with niacinamide, provitamin B5 or pantothenic acid.
  • the individual vitamins or derivatives thereof are used in the appropriate quantities between 0.5 and 3% in each case, in total in an amount of 1 to 7% by weight, based on the total weight of the preparation.
  • Preferred additional active ingredients are selected from essential oils, plant extracts, vitamins, care substances or mixtures thereof. dosage forms
  • lipid base of 25 bis 90, especially 40 to 85% by weight of lipid; 5 to 25% by weight, in particular 5-15% by weight, of dispersant; 10 2 to 10 9 , especially 10 3 to 10 7 , germs / g Preparation Probiotic microorganisms selected from bacteria of the genus Lactobacillus, Bifidus or mixtures thereof, and the remainder suitable additives / additives have.
  • Dyes, perfume substances, consistency regulators are particularly suitable additives here.
  • Such preparations are fluid to liquid, preferably low viscous.
  • Particularly suitable preparations are those which contain 45% to 82% by weight of lipid component (s) (especially natural liquid oils as described); 10 2 to 10 9 , especially 10 3 to 10 7 germs / g Preparation Probiotic microorganisms; From 5 to 25% by weight, before oylated nonionic dispersants; 0.1 to 20 wt.% Additives, optionally 0, or 0.3 to 10 wt.% Additional active ingredients.
  • preparations which contain 50 to 70% by weight of one or more of the mentioned lipid components; and from 5 to 20% by weight, in particular from 10 to 20% by weight, of one or more dispersants, in particular nonionic agents as mentioned above; 10 2 to 10 9 , especially 10 3 to 10 7 , germs / g Preparation Probiotic microorganism, optionally 1 to 8% by weight of additional active ingredients, 0.5 to 10% by weight of additives selected from dyes, perfume substances, consistency regulators.
  • solid preparations in the form of a powder / granule or a tablet are obtained from preferably 60-80% by weight mineral raisins, or from 0 to 40% mineral salts and from 80 to 40% effervescent salt, and from 0.1 to 20, in particular up to 10% by weight of additives, preferably selected from perfumes, dyes, consistency agents, in particular consistency colloids as described above (cellulose ethers, guar gum, xanthan, poloxamer-polysiloxane copolymers, starch or starch derivatives such as rice, wheat Corn and potato starch, protein hydrolysates of vegetable and / or animal origin, collagen hydrolysates).
  • additives preferably selected from perfumes, dyes, consistency agents, in particular consistency colloids as described above (cellulose ethers, guar gum, xanthan, poloxamer-polysiloxane copolymers, starch or starch derivatives such as rice, wheat Corn and potato starch, protein hydrolysates of vegetable and / or animal origin, collagen
  • Additional active ingredients present especially selected from essential oils, plant extracts, skin care substances, vitamins, and in particular 1-25% by weight, especially 2.5-20% by weight of one or more lipid components; 0.3-20% by weight, in particular 0.5-8% by weight of one or more dispersants (especially mixtures of nonionic dispersants ai) to aiv), in particular ai), aiii) and / or anionic dispersants bi), bii)); and 10 2 to 10 9 , especially 10 3 to 10 7 , germs / g Preparation Probiotic microorganism included.
  • Part or all of the mineral salts may also be replaced by a carbonate / bicarbonate salt mixture as described above.
  • mineral salts in particular salts of the cations sodium, potassium, Magnesium, calcium, iron, ammonium or manganese and the anions Hydro- gencarbonat, chloride, fluoride, sulfate or nitrate used as such or as mixtures.
  • other known from the Thermalbadmileu salts such as the cations lithium, aluminum, strontium, and in the anions lo did, bromide, thiosulfate, are used. As a result, thermal bath analogous conditions can be achieved.
  • the carbonate / bicarbonate acid mixture for this purpose is known and usually consists of 5-80% carbonate / bicarbonate, preferably 10-50%, e.g. Sodium or potassium (bi) carbonate or ammonium (bi) carbonate, potassium carbonate and 10-80%, preferably 10-50%, of an acid, in particular an organic acid, such as. Citric or tartaric acid or fumaric acid or adipic acid or mixtures thereof, or an acid anhydride such as citric or succinic anhydride; or inorganic acid salts such as sodium dihydrogen phosphate, sodium fumarate or mixtures thereof.
  • an organic acid such as. Citric or tartaric acid or fumaric acid or adipic acid or mixtures thereof, or an acid anhydride such as citric or succinic anhydride; or inorganic acid salts such as sodium dihydrogen phosphate, sodium fumarate or mixtures thereof.
  • Particularly preferred lipid components such as can be used in solid products of the invention, such as powder / granules / tablets, are e.g. hydrogenated soybean oil, hydrogenated peanut oil, in combination with natural oils as mentioned above with a total oleic acid / linoleic acid content (£) of at least 50% by weight.
  • urea may also be used as a solid carrier e.g. be used in amounts of 80 to 95 wt.%.
  • dispersing or lipid components, as well as additional additives it is possible with preference to use those components mentioned for the abovementioned solid salt administration forms, above all the consistency colloids.
  • dosage forms described above it is further preferred for 0.3 to 5% by weight of one or more vesicle formers to be present as described, above all 0.5 to 4% by weight.
  • the preparations are in particular one-part, especially single-phase, presented and include the entire mixture, from which the user can take a suitable amount, such. B. by pouring at liquid funds.
  • the packaging / outer packaging may contain instructions for the respective application quantity. Possibly. It may be advantageous to provide a smaller individual package with a suitable pre-dosed amount of preparation such as. B. smaller single container for travel, single use. This can be especially advantageous for solid products such as bath salt granules or bath salt tablets. These can then be easily applied as a single dose.
  • the preparations according to the invention are prepared in conventional apparatus (stainless steel kettle with stirrer / mixer) at room temperature. These are z. B. presented in a stainless steel container, the liquid lipids. Solid lipids, if present, are liquefied in a separate vessel by suitable means (eg heating) and added to the liquid lipids with stirring. The addition of dispersants, if appropriate vesicle-forming agents, additives or additional active ingredients, perfume oils then follows successively with stirring. The probiotic germs are finally suspended as a powder in the mixture. It is not filtered. The packaging follows directly on the production and takes place with stirring.
  • the probio- added to active ingredients Possibly. additional liquid solution is added by application, sprinkling or spraying and mixed. If desired, granulation / tableting and then packaging can be added to the powder production. The entire production takes place at room temperature.
  • the preparations described can be used both in the tub and in the shower (here liquid preparations) for partial or full baths for primarily cosmetic, or dermatological or medical purposes.
  • the appropriate amount is used by the user, generally according to an amount indicated on the package containing the preparation.
  • the preparations according to the application can therefore be used for the production of, in particular, a bathing liquor, especially a full or partial bathing liquor, or even a foot bath or a shower bath for cosmetic, dermatological or medical purposes, in particular also in connection with additional active ingredients (secondary purpose).
  • the duration of the application depends on the respective z. B. secondary target, such. B. 5 to 30 minutes bath tub / foot bath, a few minutes shower.
  • the temperature of the water should be between 33 ° C and 42 ° C, as well as in the shower or foot bath.
  • the preparations are designed in such a way that no special measures to remove any residues are to be taken after the application has been completed. Rinsing with water and / or wiping, if desired, but can be done.
  • Example 1 Probiotic preparation (liquid oil bath / oil shower)
  • Bifidobacterium BB-12 (30x 10 a 1, 00 Germs / g powder
  • Magnolia extract 1 1, 00
  • Bifidobacterium BB-12 (30x 10 a 0.35 germs / g powder
  • Lactobacillus acidophilus (30x 10 a 0.35
  • Bifido LA-5 powder (about 30x10 9 seeds per g of powder).
  • Liquid probiotics oil bath 1 g of Bifidobacterium powder as described above in 100 g of oil bath preparation yields, analogous to a normal application dosage of 30 g preparation / 100 l bath water 1x10 9 germs per 10 l bath water.
  • Plastic trays with 10 L water content are used.
  • the exactly weighed amount of bath preparation (solid / liquid) for 10 L bath water is added to the incoming bath water.
  • the water temperature is about 37 ° C to 39 ° C.
  • the duration of the bracelet is 5 minutes.
  • the arm is easily moved in the tub.
  • a skin sample of the entire previously marked area of 100 cm 2 is removed by stripping the skin and analyzed microbiologically using a suitable test stick.
  • Table 1 The results are summarized in Table 1 below:
  • Example 3 and Example 5 Test samples according to the preparations of Example 3 and Example 5 were tested according to standard tests (SOP) according to standard laboratory methods for their stabilities. The results are summarized in Table 2a, b.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne des préparations balnéologiques, cosmétiques, dermatologiques ou médicinales, solides ou liquides pour prendre un bain ou une douche, lesdites préparations étant sensiblement anhydres (avec une faible teneur en eau inférieure à 1 % en poids) et présentant des dispersants, une certaine teneur lipidique contenant, de préférence, au moins un lipide et une certaine teneur en principes actifs probiotiques, sélectionnés surtout parmi les bactéries du genre Lactobacillus et Bifidobacteria. De manière surprenante lors de l'utilisation de ces préparations, des zones cutanées mises en contact avec les principes probiotiques peuvent en bénéficier par voie topique en termes d'action de soins aux fins de conservation et éventuellement de restauration de leur état microbien sain, tout étant nettoyées et alimentées en lipides. Les préparations offrent une stabilité des micro-organismes nécessaire aux effets décrits sans autre mesure spéciale à cet effet.
PCT/EP2012/000250 2011-01-31 2012-01-19 Préparations probiotiques balnéologiques contenant des lipides et leurs utilisations Ceased WO2012104025A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP12702178.0A EP2670385A2 (fr) 2011-01-31 2012-01-19 Préparations probiotiques balnéologiques contenant des lipides et leurs utilisations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011009798.8A DE102011009798B4 (de) 2011-01-31 2011-01-31 Balneologische lipidhaltige probiotische Zubereitungen für kosmetische / dermatologische / medizinische Anwendungen
DE102011009798.8 2011-01-31

Publications (2)

Publication Number Publication Date
WO2012104025A2 true WO2012104025A2 (fr) 2012-08-09
WO2012104025A3 WO2012104025A3 (fr) 2013-01-17

Family

ID=45562268

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/000250 Ceased WO2012104025A2 (fr) 2011-01-31 2012-01-19 Préparations probiotiques balnéologiques contenant des lipides et leurs utilisations

Country Status (3)

Country Link
EP (1) EP2670385A2 (fr)
DE (1) DE102011009798B4 (fr)
WO (1) WO2012104025A2 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102014222014A1 (de) 2014-10-29 2016-05-04 Beiersdorf Ag Peelendes Reinigungsprodukt auf Ölbasis
US9486513B1 (en) 2010-02-09 2016-11-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
EP3130330A1 (fr) 2015-08-12 2017-02-15 Beiersdorf AG Produit de nettoyage basée d'huile avec particules
EP3130329A1 (fr) 2015-08-12 2017-02-15 Beiersdorf AG Produit de nettoyage base d'huile
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US9878023B1 (en) 2010-02-09 2018-01-30 David Gordon Bermudes Protease inhibitor: protease sensitive expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
WO2018081441A1 (fr) * 2016-10-26 2018-05-03 Nutech Ventures Utilisation de souches bactériennes probiotiques et d'extraits cellulaires pour inhiber l'acidose et les abcès hépatiques chez les bovins
US20200024674A1 (en) * 2017-01-13 2020-01-23 Sustainable Community Development, L.L.C., D/B/A Scd Probiotics Bio-degradable composition and/or probiotic biochemicals and methods of use in leather tanning processes
US10857233B1 (en) 2010-02-09 2020-12-08 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN114601759A (zh) * 2022-04-01 2022-06-10 广州研智化妆品有限公司 一种具有抗敏、舒缓功效的组合物
CN114917256A (zh) * 2022-04-15 2022-08-19 广西大学 用于鸡胚卵内注射的微生态制剂及其制备方法
US12378536B1 (en) 2015-05-11 2025-08-05 David Bermudes Chimeric protein toxins for expression by therapeutic bacteria

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012007734A1 (de) * 2012-04-18 2013-10-24 Merz Pharma Gmbh & Co. Kgaa Stabile, einfach aus 2 Phasen herstellbare feste Ölbadesalzzubereitungen mit anwendungsbezogener Einsatzflexibilität
US20180311144A1 (en) * 2015-10-15 2018-11-01 Natura Cosméticos S.A. Cosmetic composition having probiotic bacteria
WO2017173240A1 (fr) 2016-03-31 2017-10-05 Gojo Industries, Inc. Composition nettoyante stimulant les peptides antimicrobiens
AU2017240064B8 (en) 2016-03-31 2021-11-11 Gojo Industries, Inc. Antimicrobial peptide stimulating sanitizing composition
EP3436041B1 (fr) 2016-03-31 2023-05-24 Gojo Industries, Inc. Composition de désinfectant contenant un probiotique/prébiotique en tant que principe actif
JP2020500860A (ja) 2016-11-23 2020-01-16 ゴジョ・インダストリーズ・インコーポレイテッド プロバイオティック／プレバイオティックな有効成分を含む消毒薬組成物
WO2018098160A1 (fr) * 2016-11-23 2018-05-31 Gojo Industries, Inc. Composition nettoyante topique contenant un additif prébiotique/probiotique
IT201700011632A1 (it) * 2017-02-02 2018-08-02 Farm Procemsa S P A Composizione a base di probiotici
DE102017121066A1 (de) * 2017-08-07 2019-02-07 Boris Vestweber Zusammensetzung, insbesondere zur Pflege des Intim- oder Vaginalbereichs
DE102018106331C5 (de) * 2018-03-19 2026-04-30 Benedikt Weisensee Bakterien umfassende Zusammensetzung zur Geruchsreduzierung
FR3117025B1 (fr) * 2020-12-03 2023-12-15 Oreal Composition solide anhydre comprenant une association de tensioactifs anioniques et amphotères ou zwittérioniques et un carbonate métallique

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62175419A (ja) 1986-01-25 1987-08-01 Tomoji Tanaka 人工温泉浴剤
JPS63179829A (ja) 1987-01-21 1988-07-23 Advance Co Ltd 皮膚用抗菌剤
EP0131114B1 (fr) 1983-07-08 1988-10-26 Hüls Aktiengesellschaft Procédé de production d'une préparation sèche de bactéries, stable au stockage
JPH0341019A (ja) 1989-07-07 1991-02-21 Saburo Kawamura 浴用剤及びその製造法
DE69634171T2 (de) 1995-06-02 2006-01-19 Biofem, Inc., Irvine Mikroverkapselte Kaktobacilli für medizinische Anwendungen
EP1629846A2 (fr) 1997-04-18 2006-03-01 Ganeden Biotech, Inc. Utilisation topique de spores de bacilles probiotiques pour prévenir ou traiter les infections microbiennes
US20080107699A1 (en) 2006-10-25 2008-05-08 Mark Spigelman Method of using topical probiotics for the inhibition of surface contamination by a pathogenic microorganism and composition therefor
US20090232785A1 (en) 2005-08-01 2009-09-17 L'oreal Cosmetic and/or dermatological composition for prevention and/or treatment of sensitive or dry skin
WO2010103374A2 (fr) 2009-03-09 2010-09-16 Probiotical S.P.A. Suspension huileuse contenant des bactéries probiotiques pour des utilisations pédiatriques

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3827833C1 (fr) * 1988-08-17 1989-12-28 Horst 5419 Herschbach De Meinhardt
DE19843547B4 (de) * 1997-09-26 2007-08-02 Sebapharma Gmbh & Co. Duschöl
DE19757059A1 (de) * 1997-12-20 1999-07-01 Merz & Co Gmbh & Co Balneologische Brausetablette, Verfahren zu ihrer Herstellung und ihre Verwendung
EP1110555A1 (fr) * 1999-12-22 2001-06-27 Societe Des Produits Nestle S.A. Agent anti-adhesion de la flore pathogene de la peau
US7374750B2 (en) * 2004-05-14 2008-05-20 Jennifer Albano Probiotic containing anhydrous hair care composition
ITMI20041550A1 (it) * 2004-07-29 2004-10-29 Proge Farm Srl Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
JP4948500B2 (ja) * 2008-10-03 2012-06-06 モハン シャラッド 固形石鹸及びこれを用いた送達方法

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0131114B1 (fr) 1983-07-08 1988-10-26 Hüls Aktiengesellschaft Procédé de production d'une préparation sèche de bactéries, stable au stockage
JPS62175419A (ja) 1986-01-25 1987-08-01 Tomoji Tanaka 人工温泉浴剤
JPS63179829A (ja) 1987-01-21 1988-07-23 Advance Co Ltd 皮膚用抗菌剤
JPH0341019A (ja) 1989-07-07 1991-02-21 Saburo Kawamura 浴用剤及びその製造法
DE69634171T2 (de) 1995-06-02 2006-01-19 Biofem, Inc., Irvine Mikroverkapselte Kaktobacilli für medizinische Anwendungen
EP1629846A2 (fr) 1997-04-18 2006-03-01 Ganeden Biotech, Inc. Utilisation topique de spores de bacilles probiotiques pour prévenir ou traiter les infections microbiennes
DE69832267T2 (de) 1997-04-18 2006-08-10 Ganeden Biotech, Inc., La Jolla Oberflächige verwendung von probiotischen bacillussporen zur verhinderung oder bekämpfung von mikrobiellen infektionen
US20090232785A1 (en) 2005-08-01 2009-09-17 L'oreal Cosmetic and/or dermatological composition for prevention and/or treatment of sensitive or dry skin
US20080107699A1 (en) 2006-10-25 2008-05-08 Mark Spigelman Method of using topical probiotics for the inhibition of surface contamination by a pathogenic microorganism and composition therefor
WO2010103374A2 (fr) 2009-03-09 2010-09-16 Probiotical S.P.A. Suspension huileuse contenant des bactéries probiotiques pour des utilisations pédiatriques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAZ, pages 3925 - 3934

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9878023B1 (en) 2010-02-09 2018-01-30 David Gordon Bermudes Protease inhibitor: protease sensitive expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US11219671B1 (en) 2010-02-09 2022-01-11 David Gordon Bermudes Protease inhibitor:protease sensitive expression system, composition and methods for improving the therapeutic activity and specificity of proteins delivered by bacteria
US9486513B1 (en) 2010-02-09 2016-11-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US10954521B1 (en) 2010-02-09 2021-03-23 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US10857233B1 (en) 2010-02-09 2020-12-08 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US10364435B1 (en) 2010-02-09 2019-07-30 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US10828350B1 (en) 2014-02-14 2020-11-10 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US11147760B2 (en) 2014-10-29 2021-10-19 Beiersdorf Ag Oil-based exfoliating cleansing product
DE102014222014A1 (de) 2014-10-29 2016-05-04 Beiersdorf Ag Peelendes Reinigungsprodukt auf Ölbasis
WO2016066299A1 (fr) 2014-10-29 2016-05-06 Beiersdorf Ag Produit de nettoyage exfoliant à base d'huile
US12378536B1 (en) 2015-05-11 2025-08-05 David Bermudes Chimeric protein toxins for expression by therapeutic bacteria
DE102015215359A1 (de) 2015-08-12 2017-02-16 Beiersdorf Ag Halbfestes Reinigungsprodukt auf Ölbasis enthaltend Peelingpartikel
EP3130329A1 (fr) 2015-08-12 2017-02-15 Beiersdorf AG Produit de nettoyage base d'huile
EP3130330A1 (fr) 2015-08-12 2017-02-15 Beiersdorf AG Produit de nettoyage basée d'huile avec particules
DE102015215358A1 (de) 2015-08-12 2017-02-16 Beiersdorf Ag Halbfestes Reinigungsprodukt auf Ölbasis
WO2018081441A1 (fr) * 2016-10-26 2018-05-03 Nutech Ventures Utilisation de souches bactériennes probiotiques et d'extraits cellulaires pour inhiber l'acidose et les abcès hépatiques chez les bovins
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US20200024674A1 (en) * 2017-01-13 2020-01-23 Sustainable Community Development, L.L.C., D/B/A Scd Probiotics Bio-degradable composition and/or probiotic biochemicals and methods of use in leather tanning processes
CN114601759A (zh) * 2022-04-01 2022-06-10 广州研智化妆品有限公司 一种具有抗敏、舒缓功效的组合物
CN114601759B (zh) * 2022-04-01 2023-06-27 广州研智化妆品有限公司 一种具有抗敏、舒缓功效的组合物
CN114917256A (zh) * 2022-04-15 2022-08-19 广西大学 用于鸡胚卵内注射的微生态制剂及其制备方法

Also Published As

Publication number Publication date
EP2670385A2 (fr) 2013-12-11
DE102011009798B4 (de) 2015-03-05
DE102011009798A1 (de) 2012-08-02
WO2012104025A3 (fr) 2013-01-17

Similar Documents

Publication Publication Date Title
DE102011009798B4 (de) Balneologische lipidhaltige probiotische Zubereitungen für kosmetische / dermatologische / medizinische Anwendungen
Mohiuddin Skin care creams: formulation and use
CN110403833B (zh) 用于增强碱性有益剂的局部施用的组合物及方法
US20070141012A1 (en) Skin Care Compositions
US20100129465A1 (en) Methods and Compositions Related to Acne Treatment
KR20110131498A (ko) 패각 또는 패산호로부터 추출한 알카리용액에 은이온을 포함하는 항균제와 이를 포함하여 조성된 조성물.
WO2015195304A1 (fr) Compositions et procédés pour améliorer l'application topique d'un agent bénéfique comprenant une poudre à des particules liquides et seconde poudre
CN105816390A (zh) 一种角质调理型美白双层卸妆液及其制备方法
EP2653151B1 (fr) Compositions solides de bain a l'huile et sel simplement preparable de 2 phases avec une flexibilite d'application
JP2023138656A (ja) 発泡性皮膚外用剤
EP2317968B1 (fr) Structures liposomales formant des agglomérats isométriques, notamment des perles de bain, leur production et leur utilisation
EP2453868A2 (fr) Concentrés liquides ou fluides pour le bain ou la douche formant des protéasomes, formes galéniques de ces concentrés et leur utilisation
CN110035797A (zh) 用于治疗痤疮的局部组合物
JP2002348229A (ja) 外皮用組成物
KR101761005B1 (ko) 법제 유황을 포함하는 피부보습, 항염 및 면역 증강용 화장료 조성물 및 그 제조방법
JP2003104886A (ja) 皮膚外用剤組成物
KR20170010499A (ko) 달팽이 점액 발효여과물을 유효성분으로 하는 피부장벽 개선 및 높은 피부 흡수율을 갖는 화장료 조성물과 기능성 화장품
JP2003055188A (ja) シワ形成防止用皮膚外用剤、化粧料及び食品
WO2005063193A1 (fr) Ensemble combine et procede de traitement bioregeneratif de la peau
EP2651373B1 (fr) Préparations aqueuses pour le bain formant des liposomes présentant une forte teneur en principe actif et application desdites préparations
EP2671615A1 (fr) Additif solide de bain avec un profil de dissémination visuel et olfactoric à l'effect retardé
AU711191B2 (en) Preparations for use in cosmetics and dermatology
EP2808059A1 (fr) Additif de bain comprenant 2 composants avec un delai de liberation retardee d'un colorant dependant de la matrice
CN120531659A (zh) 一种温和控油的祛痘组合物及其制备方法
KR101621009B1 (ko) 포스파티딜콜린을 포함하는 피부 외용 조성물 및 이의 제조방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12702178

Country of ref document: EP

Kind code of ref document: A2

REEP Request for entry into the european phase

Ref document number: 2012702178

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012702178

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12702178

Country of ref document: EP

Kind code of ref document: A2